The SOLNATIDE project
Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new Coronavirus
Patients infected with the new Coronavirus (2019-nCoV, Covid-19) suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approximately 30% of Covid-2019 patients further develop life-threatening Acute Respiratory Distress Syndrome (ARDS) resulting in a very high mortality rate. To date, no medicine has been approved for the therapeutic treatment of Pulmonary Permeability Oedema and ARDS.
The SOLNATIDE project will clinically test peptide-based products targeting life-threatening pulmonary diseases (e.g. oedematous respiratory failure, acute lung injury). APEPTICO’s lead-compound Solnatide (IMP) has been designed for the therapeutic treatment of patients with Acute Respiratory Distress Syndrome (ARDS) and various forms of Pulmonary Oedema (PPO).
The new Coronavirus ((c) Shutterstock no. 1643947495 for RTDS)
Orally inhaled Solnatide has delivered clinical proof-of-concept in one Phase I and two Phase II clinical studies (EUDRACT No. 2011-000223-33, 2012-001863-64, 2013-000716-21). Currently, Solnatide is subject to a Phase IIB trial (EUDRACT No. 2017-003855-47) with clinical trials approved by competent authorities and ethics committees in Germany and Austria. The SOLNATIDE project will generate clinical trial results assessing safety, tolerability and clinical efficacy of Solnatide IMP in Covid-19 patients.
The SOLNATIDE project in a nutshell
Funding: €1.626 million
Funding: European Commission (EC) call “H2020-SC1-PHE-CORONAVIRUS-2020” (grant no. 101003595)
Project start: April 1st 2020
Duration: 21 months
Consortium: 5 partners from Austria, Germany, Italy and Spain:
RTDS Association, AT – Coordinator, Project & Communication Management
APEPTICO Forschung und Entwicklungs GmbH, AT – Scientific coordinator
BCN Peptides SA, ES
OPIS SRL, IT
Contact: RTDS Association, Dr. Natascha Miljkovic, solnatide (a) rtds-group.com, +43-(0)1-3231000-11, Lerchengasse 25/2-3, A-1080 Vienna, Austria.
Further information on SOLNATIDE project
Currently, we are preparing information to be shared on a joint website representing all 18 EU Emergency Projects (to be established soon). Stay tuned for updates!
SOLNATIDE social media channels are:
SOLNATIDE project LinkedIn showcase page
SOLNATIDE on Twitter
Other sources are:
Download the SOLNATIDE project factsheet (April 2020)